Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future
• Texas AG Paxton announces ongoing investigation into Carnival over data breach